文献速递神经肿瘤

弥漫性内生性桥脑胶质瘤适形放疗期间神经系统症状的放射剂量反应

Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma.
PubMed 文献 · J Neurooncol · 2020-02-03

该研究纳入2006至2014年在本院接受常规分割放疗(中位剂量54 Gy)的108例新诊断弥漫性内生性桥脑胶质瘤(DIPG)患者,每周评估颅神经病、小脑征和长束征相关症状。症状首次改善的中位剂量分别为颅神经病16.2 Gy、长束征19.8 Gy、小脑征21.6 Gy,多数患者在20 Gy前出现改善;颅神经病任何改善与无进展生存期和总生存期延长相关(P=0.002和P=0.008)。

要点

  • DIPG放疗中位剂量54 Gy,颅神经病、长束征、小脑征首次改善的中位剂量分别为16.2 Gy、19.8 Gy、21.6 Gy。
  • 多数患者在累积剂量20 Gy前出现神经系统症状改善。
  • 颅神经病任何改善与无进展生存期和总生存期延长相关(P=0.002和P=0.008)。

核心结论

  • 低累积放疗剂量即可使多数DIPG患者神经系统症状改善。
  • 肿瘤未累及的脑干体积影响症状改善时间。
  • 放疗期间神经系统症状改善与更优生存相关。

研究设计与样本

  • 2006年至2014年在本院接受常规分割放疗(中位剂量54 Gy)的新诊断DIPG患者108例。
  • 放疗前及放疗期间每周评估颅神经病、小脑征和长束征相关症状的存在与严重程度。
  • 按累积放疗剂量评估各类症状的变化率和幅度,采用Cox比例风险模型分析临床因素及剂量体积参数的影响。

主要发现

  • 症状首次改善的中位剂量:颅神经病16.2 Gy,长束征19.8 Gy,小脑征21.6 Gy。
  • 多数患者在20 Gy前出现改善。
  • 未受累脑干体积(单独或归一化至全脑或后颅窝体积)较大与长束征改善时间较短相关(P=0.044、P=0.033、P=0.05)。
  • 颅神经病任何改善与无进展生存期和总生存期延长相关(P=0.002和P=0.008)。
  • 肿瘤体积(无论是否归一化至全脑或后颅窝体积)与无进展生存期或总生存期无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate the rate and magnitude of neurologic symptom change during radiation therapy (RT) and impact of symptom change on survival outcomes in patients with diffuse intrinsic pontine glioma (DIPG). METHODS: From 2006 to 2014, 108 patients with newly diagnosed DIPG were treated with conventionally fractionated radiation therapy (RT) to 54 Gy (median) at our institution. The presence and severity of neurologic symptoms related to cranial neuropathy (CN) and cerebellar (CB) and long-tract (LT) signs was reviewed before and weekly during RT for each patient. The rate and magnitude of change for each symptom category was evaluated according to accumulated RT dose. The impact of clinical factors and radiation dose-volume parameters was determined using Cox proportional hazards models. RESULTS: Median dose to first sign of symptomatic improvement was 16.2 Gy (CN), 19.8 Gy (LT) and 21.6 Gy (CB). Most patients showed an improvement by 20 Gy. Larger uninvolved brainstem volume, alone or normalized to total brain (TB) or posterior fossa volume (PF), was associated with shorter time to LT sign improvement (P = 0.044, P = 0.033, and P = 0.05, respectively). Patients with any improvement in CN experienced significantly, yet modestly, prolonged progression-free survival (PFS) and overall survival (OS) (P = 0.002 and P = 0.008, respectively). Tumor volume, with or without normalization to TB or PF, was not significantly associated with PFS or OS. CONCLUSIONS: Low cumulative RT doses resulted in neurologic improvement in most patients with DIPG. The volume of brainstem spared by tumor influenced time to symptomatic improvement. Neurologic improvement during RT was associated with superior survival.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tinkle CL, Campbell K, Han Y, et al. Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma. J Neurooncol. 2020. PMID: 32016716. doi:10.1007/s11060-020-03415-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。